PMC+1 Further, their original authorisation and indication were for glucose-controlnot for long-term, standalone obesity treatment
While mild, transient burning at the injection site is generally benign, certain signs and symptoms warrant prompt medical evaluation
English Bringing a wealth of experience and expertise, Stephanie is a seasoned practitioner certified as a Reiki Master, Meditation Guide, Life Coach, and Holistic Nutritionist
Hormonal treatment options include: Combined oral contraceptives : Continuous or cyclic regimens can reduce menstrual flow and suppress endometrial tissue activity Progestins : Available as oral medications, injections (depot medroxyprogesterone acetate), intrauterine devices (levonorgestrel-releasing IUD), or implants GnRH agonists : These medications induce a temporary menopausal state, effectively suppressing endometriosis but requiring add-back hormone therapy to minimize bone loss and vasomotor symptoms GnRH antagonists : FDA-approved oral options include elagolix (Orilissa) and relugolix/estradiol/norethindrone (Myfembree) with specific duration limits based on dosing and bone health considerations Aromatase inhibitors : Sometimes used in refractory cases, though not FDA-approved for this indication Bone mineral density monitoring is recommended for patients on long-term GnRH agonists or antagonists, particularly at higher doses or extended durations
